GSK secures global rights to Hutchmed's dual-target cancer therapy in $110M upfront deal
GSK has agreed to pay Hutchmed $110 million upfront to license its antibody-drug conjugate targeting KRAS and EGFR, with additional milestone payments potentially reaching $1.185 billion. The deal grants GSK rights to the experimental cancer therapy. Hutchmed, a Chinese biopharmaceutical company, disclosed the agreement.
The agreement positions GSK to develop and commercialize Hutchmed's experimental antibody-drug conjugate, a therapy designed to attack tumors through two distinct biological pathways. Hutchmed stands to receive up to $1.185 billion in additional milestone payments if the drug meets specified development and commercial targets, making the deal's total value potentially substantial for the Chinese biopharmaceutical firm.
Antibody-drug conjugates represent a growing area of oncology research, combining targeted antibodies with potent cell-killing agents. By focusing on KRAS and EGFR—two proteins frequently implicated in cancer growth—the therapy could address tumor types that have historically resisted treatment. The upfront payment signals GSK's confidence in the asset's early-stage promise, though the drug remains experimental and unproven in late-stage trials.
This deal could accelerate the development of a novel cancer therapy targeting two well-known oncogenic pathways, potentially offering new options for patients with tumors driven by KRAS or EGFR mutations. If successful, the drug may expand treatment choices for cancers that currently have limited targeted therapies. The partnership also reflects a broader industry pattern of Western pharmaceutical companies seeking innovative assets from Chinese biotech firms, which could influence global drug pricing, access, and the competitive landscape in oncology—though clinical outcomes and regulatory approvals remain uncertain.